Lisata Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Lisata Therapeutics

13/08/2024 05:31

* Lisata Therapeutics Inc  LSTA.OQ  reported a quarterly
adjusted
loss of 61 cents​​ per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of -50 cents.  The mean expectation of two analysts for the
quarter was for a loss of 76 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Lisata Therapeutics Inc's reported EPS for the quarter was
a
loss of 61 cents​.
    * The company reported a quarterly loss of $5.04 million.
    * Lisata Therapeutics Inc shares had fallen by 15.9% this
quarter and gained 7.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Lisata
Therapeutics Inc is $14.50 
This summary was machine generated from LSEG data August 13 at
04:31 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.76          -0.61          Beat
 Mar. 31 2024      -0.72          -0.65          Beat
 Dec. 31 2023      -0.93          -0.66          Beat
 Sep. 30 2023      -0.93          -0.65          Beat